MX2021013083A - Derivados de fosfato de glicero-manno-heptosa y su uso para modular una respuesta inmune. - Google Patents

Derivados de fosfato de glicero-manno-heptosa y su uso para modular una respuesta inmune.

Info

Publication number
MX2021013083A
MX2021013083A MX2021013083A MX2021013083A MX2021013083A MX 2021013083 A MX2021013083 A MX 2021013083A MX 2021013083 A MX2021013083 A MX 2021013083A MX 2021013083 A MX2021013083 A MX 2021013083A MX 2021013083 A MX2021013083 A MX 2021013083A
Authority
MX
Mexico
Prior art keywords
immune response
modulating
heptose
manno
glycero
Prior art date
Application number
MX2021013083A
Other languages
English (en)
Inventor
Tian Xu
Cong Xu
Danyang Liu
Jieqing Fan
Original Assignee
Shanghai Yao Yuan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yao Yuan Biotechnology Co Ltd filed Critical Shanghai Yao Yuan Biotechnology Co Ltd
Publication of MX2021013083A publication Critical patent/MX2021013083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I), (ver fórmula) (I) en donde R1 , R2 , R5 , R6 , R7 , L 1 , L 2 , W1 , W2 y Z 1 son como se definen en este documento, y las composiciones que lo comprenden y los métodos relacionados con la activación de la alfa-cinasa 1 (ALPK1) para modular una respuesta inmune y tratar o prevenir cáncer, infecciones, inflamación y enfermedades y trastornos relacionados, así como potenciar una respuesta inmune a un antígeno objetivo. MX/E/2022/00422.
MX2021013083A 2019-04-26 2020-04-24 Derivados de fosfato de glicero-manno-heptosa y su uso para modular una respuesta inmune. MX2021013083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019084582 2019-04-26
PCT/CN2020/086688 WO2020216326A1 (en) 2019-04-26 2020-04-24 Derivatives of glycero-manno-heptose phosphate and their use in modulating an immune response

Publications (1)

Publication Number Publication Date
MX2021013083A true MX2021013083A (es) 2022-01-24

Family

ID=72940867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013083A MX2021013083A (es) 2019-04-26 2020-04-24 Derivados de fosfato de glicero-manno-heptosa y su uso para modular una respuesta inmune.

Country Status (10)

Country Link
US (1) US20220213135A1 (es)
EP (1) EP3959220A1 (es)
JP (1) JP2022529855A (es)
KR (1) KR20220012241A (es)
CN (1) CN114391017A (es)
AU (1) AU2020263456A1 (es)
CA (1) CA3134762A1 (es)
IL (1) IL287537A (es)
MX (1) MX2021013083A (es)
WO (1) WO2020216326A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117517657B (zh) * 2024-01-08 2024-04-09 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ872300A0 (en) * 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
JPWO2007119815A1 (ja) * 2006-04-14 2009-08-27 協和発酵キリン株式会社 Ｔｏｌｌ様受容体９作動薬
GB0919070D0 (en) * 2009-10-30 2009-12-16 Univ East Anglia Compounds and their uses in glycosyltransferase binding assays

Also Published As

Publication number Publication date
JP2022529855A (ja) 2022-06-24
US20220213135A1 (en) 2022-07-07
WO2020216326A1 (en) 2020-10-29
CA3134762A1 (en) 2020-10-29
IL287537A (en) 2021-12-01
KR20220012241A (ko) 2022-02-03
AU2020263456A1 (en) 2021-12-16
CN114391017A (zh) 2022-04-22
EP3959220A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
MY196582A (en) PD-1/PD-L1 Inhibitors
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
MX2021002804A (es) Terapias de combinacion.
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
MX2021002805A (es) Terapias de combinacion.
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2021010916A (es) Inhibidores rad51.
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
ZA202208541B (en) Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
MX2021013083A (es) Derivados de fosfato de glicero-manno-heptosa y su uso para modular una respuesta inmune.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2022000308A (es) Formulacion de nanoparticulas de inhibidor de bcl-2.
MX2021012543A (es) Compuestos de indoles quirales y su uso.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.